Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

.release-content span.prnews_span{font-size:8pt;font-family:"Arial";color:black}.release-content a.prnews_a{color:blue}.release-content li.prnews_li{font-size:8pt;font-family:"Arial";color:black}.release-content p.prnews_p{font-size:0.62em;font-family:"Arial";color:black;margin:0in}.release-content .prngen2{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen4{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen3{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen17{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen18{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 3PT double;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen5{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen10{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen7{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen14{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen6{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen11{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen16{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 3PT double;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen13{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen15{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 3PT double;border-left:black 1pt}.release-content .prngen8{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen12{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen9{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prntal{text-align:LEFT}.release-content .prnml4{margin-top:0em;margin-right:0em;margin-bottom:0em;margin-left:0.33em !important}.release-content .prnml10{margin-top:0em;margin-right:0em;margin-bottom:0em;margin-left:0.83em !important}.release-content .prnml8{margin-top:0em;margin-right:0em;margin-bottom:0em;margin-left:0.67em !important}.release-content .prnbcc{border-collapse:COLLAPSE}.release-content .prntac{text-align:CENTER}

Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Şirketle ilgili diğer haberler